GA1
MCID: GLT035
MIFTS: 44

Glutaric Acidemia I (GA1)

Categories: Genetic diseases, Metabolic diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Glutaric Acidemia I

MalaCards integrated aliases for Glutaric Acidemia I:

Name: Glutaric Acidemia I 57 25
Glutaryl-Coa Dehydrogenase Deficiency 57 76 53 25 59 75
Glutaric Aciduria, Type 1 29 6 73
Glutaric Acidemia Type I 53 25 75
Glutaric Acidemia Type 1 53 25 59
Ga1 57 59 75
Glutaricaciduria, Type I 57 13
Glutaric Aciduria I 57 25
Glutaric Aciduria 1 53 75
Ga I 57 25
Glutaryl-Coenzyme a Dehydrogenase Deficiency 59
Glutaryl-Coenzyme a Dehydrogenase 13
Glutaric Aciduria, Type I 76
Brain Diseases, Metabolic 44
Glutaric Aciduria Type 1 59
Glutaricaciduria, Type 1 40
Glutaric Acidemia 1 53
Glutaricaciduria I 76
Gcdhd 59
Ga 1 53
Ga-I 75

Characteristics:

Orphanet epidemiological data:

59
glutaryl-coa dehydrogenase deficiency
Inheritance: Autosomal recessive; Prevalence: >1/1000,1-9/100000,1-9/100000 (Worldwide); Age of onset: Infancy,Neonatal; Age of death: adolescent,late childhood;

OMIM:

57
Inheritance:
autosomal recessive

Miscellaneous:
variable clinical presentation ranging from acute onset to normal adult
prevalent in old order amish of lancaster county, pennsylvania and saulteaux/ojibway indians of canada
onset of illness often associated with acute infection
worldwide frequency of 1 in 100,000 infants


HPO:

32
glutaric acidemia i:
Inheritance autosomal recessive inheritance


Classifications:



Summaries for Glutaric Acidemia I

NIH Rare Diseases : 53 Glutaric acidemia type I (GA1) is a genetic metabolic disorder. People with GA1 don't make enough of one of the enzymes needed to break down certain amino acids found in the proteins we eat. Without enough of the enzyme, the breakdown products of these amino acids build up in tissues of the body. The buildup of these chemicals can damage the brain, especially the area of the brain called the basal ganglia. The basal ganglia helps control the body's movements.  Without treatment, newborns with GA1 may at first not have any symptoms other than possibly having a slightly large head. Some, however, may have weak muscles and early signs of developmental delay. For most children with GA1, if untreated, an infection or fever will trigger an episode that causes serious damage to the basal ganglia. In some children, the brain damage will happen without a triggering fever. Damage to the basal ganglia will make it hard for the child to control the movements of their body. The damage cannot be reversed. However if treatment is started in a newborn with GA1 before symptoms begin, 80-90% of people with GA1 will not develop symptoms. Treatment however must be followed strictly, especially for the first six years of life. Treatment includes a low-lysine diet, carnitine supplementaion, and emergency treatment during an fever or acute episode. GA1 is caused by mutations in the GCDH gene and is inherited in an autosomal recessive manner. GA1 is included on the newborn screening panel in most countries. 

MalaCards based summary : Glutaric Acidemia I, also known as glutaryl-coa dehydrogenase deficiency, is related to striatonigral degeneration, infantile and branched-chain keto acid dehydrogenase kinase deficiency, and has symptoms including opisthotonus and muscle rigidity. An important gene associated with Glutaric Acidemia I is GCDH (Glutaryl-CoA Dehydrogenase). The drugs Lidocaine and Epinephrine have been mentioned in the context of this disorder. Affiliated tissues include brain, eye and testes, and related phenotypes are macrocephaly and joint dislocation

Genetics Home Reference : 25 Glutaric acidemia type I is an inherited disorder in which the body is unable to process certain proteins properly. People with this disorder have inadequate levels of an enzyme that helps break down the amino acids lysine, hydroxylysine, and tryptophan, which are building blocks of protein. Excessive levels of these amino acids and their intermediate breakdown products can accumulate and cause damage to the brain, particularly the basal ganglia, which are regions that help control movement. Intellectual disability may also occur.

OMIM : 57 Glutaric acidemia I is an autosomal recessive metabolic disorder characterized by gliosis and neuronal loss in the basal ganglia and a progressive movement disorder that usually begins during the first year of life (Goodman et al., 1995). Hedlund et al. (2006) provided a detailed review of the clinical and biochemical aspects of glutaric acidemia type I. (231670)

UniProtKB/Swiss-Prot : 75 Glutaric aciduria 1: An autosomal recessive metabolic disorder characterized by progressive dystonia and athetosis due to gliosis and neuronal loss in the basal ganglia.

Wikipedia : 76 Glutaric acidemia type 1 (or "glutaric aciduria", "GA1", or "GAT1") is an inherited disorder in which... more...

Related Diseases for Glutaric Acidemia I

Graphical network of the top 20 diseases related to Glutaric Acidemia I:



Diseases related to Glutaric Acidemia I

Symptoms & Phenotypes for Glutaric Acidemia I

Symptoms via clinical synopsis from OMIM:

57
Head And Neck Head:
macrocephaly

Abdomen Liver:
hepatomegaly

Neurologic Central Nervous System:
dystonia
rigidity
choreoathetosis
spastic diplegia
opisthotonus
more
Growth Other:
failure to thrive

Laboratory Abnormalities:
hypoglycemia
metabolic acidosis
ketonuria
glutaricaciduria
glutaryl-coa dehydrogenase deficiency
more

Clinical features from OMIM:

231670

Human phenotypes related to Glutaric Acidemia I:

59 32 (show all 46)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 macrocephaly 59 32 frequent (33%) Frequent (79-30%) HP:0000256
2 joint dislocation 59 32 frequent (33%) Frequent (79-30%) HP:0001373
3 abnormality of eye movement 59 32 occasional (7.5%) Occasional (29-5%) HP:0000496
4 seizures 59 32 occasional (7.5%) Occasional (29-5%) HP:0001250
5 muscular hypotonia 59 32 frequent (33%) Frequent (79-30%) HP:0001252
6 spasticity 59 32 frequent (33%) Frequent (79-30%) HP:0001257
7 gait disturbance 59 32 occasional (7.5%) Occasional (29-5%) HP:0001288
8 neurological speech impairment 59 32 occasional (7.5%) Occasional (29-5%) HP:0002167
9 developmental regression 59 32 occasional (7.5%) Occasional (29-5%) HP:0002376
10 abnormal facial shape 59 32 frequent (33%) Frequent (79-30%) HP:0001999
11 dyskinesia 59 32 hallmark (90%) Very frequent (99-80%) HP:0100660
12 feeding difficulties in infancy 59 32 frequent (33%) Frequent (79-30%) HP:0008872
13 cognitive impairment 59 32 occasional (7.5%) Occasional (29-5%) HP:0100543
14 vomiting 59 32 hallmark (90%) Very frequent (99-80%) HP:0002013
15 prominent forehead 59 32 frequent (33%) Frequent (79-30%) HP:0011220
16 irritability 59 32 frequent (33%) Frequent (79-30%) HP:0000737
17 dystonia 59 32 hallmark (90%) Very frequent (99-80%) HP:0001332
18 migraine 59 32 occasional (7.5%) Occasional (29-5%) HP:0002076
19 cerebral ischemia 59 32 occasional (7.5%) Occasional (29-5%) HP:0002637
20 abnormality of the retinal vasculature 59 32 occasional (7.5%) Occasional (29-5%) HP:0008046
21 malignant hyperthermia 59 32 occasional (7.5%) Occasional (29-5%) HP:0002047
22 vertigo 59 32 occasional (7.5%) Occasional (29-5%) HP:0002321
23 coma 59 32 occasional (7.5%) Occasional (29-5%) HP:0001259
24 intracranial hemorrhage 59 32 occasional (7.5%) Occasional (29-5%) HP:0002170
25 abnormality of extrapyramidal motor function 59 32 frequent (33%) Frequent (79-30%) HP:0002071
26 choreoathetosis 59 32 frequent (33%) Frequent (79-30%) HP:0001266
27 large fontanelles 59 32 hallmark (90%) Very frequent (99-80%) HP:0000239
28 metabolic acidosis 59 32 hallmark (90%) Very frequent (99-80%) HP:0001942
29 hemiplegia 59 32 occasional (7.5%) Occasional (29-5%) HP:0002301
30 encephalopathy 59 32 hallmark (90%) Very frequent (99-80%) HP:0001298
31 failure to thrive 32 HP:0001508
32 hepatomegaly 32 HP:0002240
33 hypoglycemia 32 HP:0001943
34 abnormality of movement 59 Frequent (79-30%)
35 rigidity 32 HP:0002063
36 generalized hypotonia 32 HP:0001290
37 spastic diplegia 32 HP:0001264
38 opisthotonus 32 HP:0002179
39 ketonuria 32 HP:0002919
40 symmetrical progressive peripheral demyelination 32 HP:0006873
41 dilation of lateral ventricles 32 HP:0006956
42 delayed myelination 32 HP:0012448
43 infantile encephalopathy 32 HP:0007105
44 ketonemia 32 HP:0410175
45 glutaric aciduria 32 HP:0003150
46 glutaric acidemia 32 HP:0003530

UMLS symptoms related to Glutaric Acidemia I:


opisthotonus, muscle rigidity

Drugs & Therapeutics for Glutaric Acidemia I

Drugs for Glutaric Acidemia I (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 44)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lidocaine Approved, Vet_approved Phase 1 137-58-6 3676
2
Epinephrine Approved, Vet_approved Phase 1 51-43-4 5816
3
Racepinephrine Approved Phase 1 329-65-7 838
4
Proguanil Approved Phase 1 500-92-5 4923
5
Atovaquone Approved Phase 1 95233-18-4 74989
6
Lumefantrine Approved Phase 1 82186-77-4 6437380
7
Artemether Approved Phase 1 71963-77-4 119380 68911
8 Autonomic Agents Phase 1
9 Anesthetics Phase 1
10 Sympathomimetics Phase 1
11 Adrenergic alpha-Agonists Phase 1
12 Adrenergic beta-Agonists Phase 1
13 Mydriatics Phase 1
14 Neurotransmitter Agents Phase 1
15 Anesthetics, Local Phase 1
16 Adrenergic Agonists Phase 1
17 Pharmaceutical Solutions Phase 1
18 Diuretics, Potassium Sparing Phase 1
19 Peripheral Nervous System Agents Phase 1
20 Sodium Channel Blockers Phase 1
21 Adrenergic Agents Phase 1
22 Anti-Arrhythmia Agents Phase 1
23 Respiratory System Agents Phase 1
24 Epinephryl borate Phase 1
25 Central Nervous System Depressants Phase 1
26 Anti-Asthmatic Agents Phase 1
27 Vasoconstrictor Agents Phase 1
28 Bronchodilator Agents Phase 1
29 Anti-Infective Agents Phase 1
30 Antimalarials Phase 1
31 Artemether-lumefantrine combination Phase 1
32 Immunologic Factors Phase 1
33 Antiparasitic Agents Phase 1
34 Antiprotozoal Agents Phase 1
35 Vaccines Phase 1
36
Methimazole Approved 60-56-0 1349907
37
Ganciclovir Approved, Investigational 82410-32-0 3454
38 gastric inhibitory polypeptide Not Applicable
39 Hormones, Hormone Substitutes, and Hormone Antagonists Not Applicable
40 Incretins Not Applicable
41 Gastrointestinal Agents Not Applicable
42 Hormones Not Applicable
43 Hormone Antagonists Not Applicable
44 Ganciclovir triphosphate

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Dental Anesthesia in Pregnant Women With Rheumatic Heart Disease Completed NCT00482573 Phase 1
2 Safety and Protective Efficacy of Genetically Attenuated PfSPZ-GA1 Vaccine in Healthy Dutch Volunteers Recruiting NCT03163121 Phase 1
3 GIP Receptor Antagonist Studies in Humans Completed NCT02747472 Not Applicable GIP-A;GIP(1-42)
4 Characteristics of Islet β-cell Functions in Chinese Patients With Graves' Disease Completed NCT02376088 Methimazole
5 Neurodevelopmental Outcome of Early Dietary Lysine Restriction in Pyridoxine Dependent Epilepsy Patients Withdrawn NCT01795170 Pyridoxine

Search NIH Clinical Center for Glutaric Acidemia I

Cochrane evidence based reviews: brain diseases, metabolic

Genetic Tests for Glutaric Acidemia I

Genetic tests related to Glutaric Acidemia I:

# Genetic test Affiliating Genes
1 Glutaric Aciduria, Type 1 29 GCDH

Anatomical Context for Glutaric Acidemia I

MalaCards organs/tissues related to Glutaric Acidemia I:

41
Brain, Eye, Testes

Publications for Glutaric Acidemia I

Articles related to Glutaric Acidemia I:

(show all 50)
# Title Authors Year
1
Heterozygosity for an in-frame deletion causes glutaryl-CoA dehydrogenase deficiency in a patient detected by newborn screening: investigation of the effect of the mutant allele. ( 22231382 )
2012
2
Neonatal astrocyte damage is sufficient to trigger progressive striatal degeneration in a rat model of glutaric acidemia-I. ( 21698251 )
2011
3
Teaching NeuroImages: Glutaric aciduria type 1 (glutaryl-CoA dehydrogenase deficiency). ( 21727264 )
2011
4
Safety, efficacy and physiological actions of a lysine-free, arginine-rich formula to treat glutaryl-CoA dehydrogenase deficiency: focus on cerebral amino acid influx. ( 21820344 )
2011
5
Glutaric aciduria type 1 in South Africa-high incidence of glutaryl-CoA dehydrogenase deficiency in black South Africans. ( 20732827 )
2010
6
Astrocytic proliferation and mitochondrial dysfunction induced by accumulated glutaric acidemia I (GAI) metabolites: possible implications for GAI pathogenesis. ( 18930146 )
2008
7
Classic and late-onset neurological disease in two siblings with glutaryl-CoA dehydrogenase deficiency. ( 17957492 )
2007
8
Biochemistry and bioenergetics of glutaryl-CoA dehydrogenase deficiency. ( 17879145 )
2007
9
Guideline for the diagnosis and management of glutaryl-CoA dehydrogenase deficiency (glutaric aciduria type I). ( 17203377 )
2007
10
Multimodal imaging of striatal degeneration in Amish patients with glutaryl-CoA dehydrogenase deficiency. ( 17478444 )
2007
11
Decline of acute encephalopathic crises in children with glutaryl-CoA dehydrogenase deficiency identified by newborn screening in Germany. ( 17622945 )
2007
12
Glutaryl-CoA dehydrogenase deficiency. ( 17211155 )
2007
13
Natural history, outcome, and treatment efficacy in children and adults with glutaryl-CoA dehydrogenase deficiency. ( 16641220 )
2006
14
Riboflavin-responsive glutaryl CoA dehydrogenase deficiency. ( 16377226 )
2006
15
Intracerebral accumulation of glutaric and 3-hydroxyglutaric acids secondary to limited flux across the blood-brain barrier constitute a biochemical risk factor for neurodegeneration in glutaryl-CoA dehydrogenase deficiency. ( 16573641 )
2006
16
Late-onset neurologic disease in glutaryl-CoA dehydrogenase deficiency. ( 15985591 )
2005
17
Glutaric acid and its metabolites cause apoptosis in immature oligodendrocytes: a novel mechanism of white matter degeneration in glutaryl-CoA dehydrogenase deficiency. ( 15774829 )
2005
18
Glutaconyl-CoA is the main toxic agent in glutaryl-CoA dehydrogenase deficiency (glutaric aciduria type I). ( 15922108 )
2005
19
Glutaryl-CoA dehydrogenase deficiency and newborn screening: retrospective analysis of a low excretor provides further evidence that some cases may be missed. ( 16183314 )
2005
20
Nuclear magnetic resonance spectroscopy in glutaryl-CoA dehydrogenase deficiency. ( 15505395 )
2004
21
Neonatal screening for glutaryl-CoA dehydrogenase deficiency. ( 15505392 )
2004
22
Animal models for glutaryl-CoA dehydrogenase deficiency. ( 15505386 )
2004
23
Modulation of glutamatergic and GABAergic neurotransmission in glutaryl-CoA dehydrogenase deficiency. ( 15505388 )
2004
24
Maintenance treatment of glutaryl-CoA dehydrogenase deficiency. ( 15505396 )
2004
25
Correlation of genotype and phenotype in glutaryl-CoA dehydrogenase deficiency. ( 15505393 )
2004
26
Pathomechanisms of neurodegeneration in glutaryl-CoA dehydrogenase deficiency. ( 14705106 )
2004
27
Development of pathogenic concepts in glutaryl-CoA dehydrogenase deficiency: the challenge. ( 15505384 )
2004
28
Excitotoxicity and bioenergetics in glutaryl-CoA dehydrogenase deficiency. ( 15505385 )
2004
29
Challenges for basic research in glutaryl-CoA dehydrogenase deficiency. ( 15505391 )
2004
30
Neuroradiological findings in glutaric aciduria type I (glutaryl-CoA dehydrogenase deficiency). ( 15505394 )
2004
31
Emergency treatment in glutaryl-CoA dehydrogenase deficiency. ( 15505397 )
2004
32
Reduction of lysine intake while avoiding malnutrition--major goals and major problems in dietary treatment of glutaryl-CoA dehydrogenase deficiency. ( 15505398 )
2004
33
Management of movement disorders in glutaryl-CoA dehydrogenase deficiency: anticholinergic drugs and botulinum toxin as additional therapeutic options. ( 15505399 )
2004
34
Looking forward--an evidence-based approach to glutaryl-CoA dehydrogenase deficiency. ( 15505401 )
2004
35
Glutaryl-CoA dehydrogenase deficiency: region-specific analysis of organic acids and acylcarnitines in post mortem brain predicts vulnerability of the putamen. ( 14598231 )
2003
36
3-Hydroxyglutarate excretion is increased in ketotic patients: implications for glutaryl-CoA dehydrogenase deficiency testing. ( 12118531 )
2002
37
Evidence of a single origin for the most frequent mutation (R402W) causing glutaryl-CoA dehydrogenase deficiency: identification of 3 novel polymorphisms and haplotype definition. ( 10649503 )
2000
38
Glutaryl-CoA dehydrogenase deficiency in Spain: evidence of two groups of patients, genetically, and biochemically distinct. ( 10960496 )
2000
39
Maturation-dependent neurotoxicity of 3-hydroxyglutaric and glutaric acids in vitro: a new pathophysiologic approach to glutaryl-CoA dehydrogenase deficiency. ( 10759157 )
2000
40
Glutaryl-CoA dehydrogenase deficiency presenting as 3-hydroxyglutaric aciduria. ( 10066389 )
1999
41
Glutaric aciduria type 1 (glutaryl-CoA-dehydrogenase deficiency): advances and unanswered questions. Report from an international meeting. ( 9392391 )
1997
42
Clinical course, early diagnosis, treatment, and prevention of disease in glutaryl-CoA dehydrogenase deficiency. ( 8837070 )
1996
43
Variable clinical and biochemical presentation of seven Spanish cases with glutaryl-CoA-dehydrogenase deficiency. ( 8552212 )
1995
44
Early signs and course of disease of glutaryl-CoA dehydrogenase deficiency. ( 7564239 )
1995
45
Prenatal diagnosis of glutaryl-CoA dehydrogenase deficiency: experience using first-trimester chorionic villus sampling. ( 8084854 )
1994
46
The segregation of glutaryl-CoA dehydrogenase deficiency and Refsum syndrome in a family. ( 7528828 )
1994
47
First trimester prenatal exclusion of glutaryl-CoA dehydrogenase deficiency (glutaric aciduria type 1). ( 2512425 )
1989
48
Early prenatal diagnosis in two pregnancies at risk for glutaryl-CoA dehydrogenase deficiency. ( 2512426 )
1989
49
Treatment of glutaryl-CoA dehydrogenase deficiency (glutaric aciduria). Experience with diet, riboflavin, and GABA analogue. ( 430318 )
1979
50
Ketotic episodes in glutaryl-CoA dehydrogenase deficiency (glutaric aciduria). ( 503664 )
1979

Variations for Glutaric Acidemia I

UniProtKB/Swiss-Prot genetic disease variations for Glutaric Acidemia I:

75 (show top 50) (show all 58)
# Symbol AA change Variation ID SNP ID
1 GCDH p.Arg88Cys VAR_000366 rs142967670
2 GCDH p.Arg94Leu VAR_000367
3 GCDH p.Gly101Arg VAR_000368 rs127316483
4 GCDH p.Cys115Tyr VAR_000369 rs776758971
5 GCDH p.Ala122Val VAR_000370 rs766325846
6 GCDH p.Arg128Gly VAR_000371
7 GCDH p.Arg138Gly VAR_000372 rs897036690
8 GCDH p.Ser139Leu VAR_000373 rs139851890
9 GCDH p.Val148Ile VAR_000374
10 GCDH p.Arg161Gln VAR_000375 rs777201305
11 GCDH p.Gly178Arg VAR_000376 rs749452002
12 GCDH p.Leu179Arg VAR_000377 rs774526353
13 GCDH p.Met191Thr VAR_000378 rs149120354
14 GCDH p.Ala195Thr VAR_000379
15 GCDH p.Arg227Pro VAR_000380 rs121434373
16 GCDH p.Phe236Leu VAR_000381 rs747920711
17 GCDH p.Arg257Gln VAR_000382 rs751583656
18 GCDH p.Arg257Trp VAR_000383 rs766518430
19 GCDH p.Met266Val VAR_000384
20 GCDH p.Pro278Ser VAR_000385 rs751742575
21 GCDH p.Leu283Pro VAR_000386
22 GCDH p.Ala293Thr VAR_000387 rs121434371
23 GCDH p.Arg294Trp VAR_000388
24 GCDH p.Tyr295His VAR_000389 rs121434366
25 GCDH p.Ser305Leu VAR_000392 rs126058018
26 GCDH p.Cys308Ser VAR_000393 rs120536899
27 GCDH p.Leu309Trp VAR_000394 rs124771289
28 GCDH p.Arg313Trp VAR_000395 rs779315456
29 GCDH p.Gln333Glu VAR_000396 rs794726972
30 GCDH p.Ala349Thr VAR_000397 rs125729263
31 GCDH p.Gly354Arg VAR_000398
32 GCDH p.Gly354Ser VAR_000399 rs768925619
33 GCDH p.Arg355Cys VAR_000400 rs781477694
34 GCDH p.Arg355His VAR_000401 rs748275416
35 GCDH p.Glu365Lys VAR_000402 rs121434370
36 GCDH p.Cys375Arg VAR_000403 rs134897476
37 GCDH p.Ala382Thr VAR_000404 rs567564095
38 GCDH p.Arg383Cys VAR_000405 rs150938052
39 GCDH p.Arg383His VAR_000406 rs764608975
40 GCDH p.Arg386Gln VAR_000407 rs398123190
41 GCDH p.Gly390Arg VAR_000408 rs372983141
42 GCDH p.Gly390Ala VAR_000409 rs778153326
43 GCDH p.Asn392Asp VAR_000410
44 GCDH p.Val400Met VAR_000411 rs121434372
45 GCDH p.Arg402Trp VAR_000412 rs121434369
46 GCDH p.Arg402Gln VAR_000413 rs786204626
47 GCDH p.His403Arg VAR_000414
48 GCDH p.Asn406Lys VAR_000415
49 GCDH p.Leu407Pro VAR_000416
50 GCDH p.Glu414Lys VAR_000417 rs147611168

ClinVar genetic disease variations for Glutaric Acidemia I:

6 (show top 50) (show all 313)
# Gene Variation Type Significance SNP ID Assembly Location
1 GCDH NM_000159.3(GCDH): c.883T> C (p.Tyr295His) single nucleotide variant Pathogenic rs121434366 GRCh37 Chromosome 19, 13007754: 13007754
2 GCDH NM_000159.3(GCDH): c.883T> C (p.Tyr295His) single nucleotide variant Pathogenic rs121434366 GRCh38 Chromosome 19, 12896940: 12896940
3 GCDH NM_000159.3(GCDH): c.1262C> T (p.Ala421Val) single nucleotide variant Pathogenic rs121434367 GRCh37 Chromosome 19, 13010300: 13010300
4 GCDH NM_000159.3(GCDH): c.1262C> T (p.Ala421Val) single nucleotide variant Pathogenic rs121434367 GRCh38 Chromosome 19, 12899486: 12899486
5 GCDH NM_000159.3(GCDH): c.877G> A (p.Ala293Thr) single nucleotide variant Pathogenic rs121434371 GRCh37 Chromosome 19, 13007748: 13007748
6 GCDH NM_000159.3(GCDH): c.877G> A (p.Ala293Thr) single nucleotide variant Pathogenic rs121434371 GRCh38 Chromosome 19, 12896934: 12896934
7 GCDH NM_000159.3(GCDH): c.1247C> T (p.Thr416Ile) single nucleotide variant Pathogenic rs121434368 GRCh37 Chromosome 19, 13010285: 13010285
8 GCDH NM_000159.3(GCDH): c.1247C> T (p.Thr416Ile) single nucleotide variant Pathogenic rs121434368 GRCh38 Chromosome 19, 12899471: 12899471
9 GCDH NM_000159.3(GCDH): c.1204C> T (p.Arg402Trp) single nucleotide variant Pathogenic/Likely pathogenic rs121434369 GRCh37 Chromosome 19, 13008638: 13008638
10 GCDH NM_000159.3(GCDH): c.1204C> T (p.Arg402Trp) single nucleotide variant Pathogenic/Likely pathogenic rs121434369 GRCh38 Chromosome 19, 12897824: 12897824
11 GCDH NM_000159.3(GCDH): c.1093G> A (p.Glu365Lys) single nucleotide variant Pathogenic rs121434370 GRCh37 Chromosome 19, 13008527: 13008527
12 GCDH NM_000159.3(GCDH): c.1093G> A (p.Glu365Lys) single nucleotide variant Pathogenic rs121434370 GRCh38 Chromosome 19, 12897713: 12897713
13 GCDH GCDH, IVS1, G-T, +5 single nucleotide variant Pathogenic
14 GCDH NM_000159.3(GCDH): c.1198G> A (p.Val400Met) single nucleotide variant Pathogenic/Likely pathogenic rs121434372 GRCh37 Chromosome 19, 13008632: 13008632
15 GCDH NM_000159.3(GCDH): c.1198G> A (p.Val400Met) single nucleotide variant Pathogenic/Likely pathogenic rs121434372 GRCh38 Chromosome 19, 12897818: 12897818
16 GCDH NM_000159.3(GCDH): c.680G> C (p.Arg227Pro) single nucleotide variant Pathogenic/Likely pathogenic rs121434373 GRCh37 Chromosome 19, 13007063: 13007063
17 GCDH NM_000159.3(GCDH): c.680G> C (p.Arg227Pro) single nucleotide variant Pathogenic/Likely pathogenic rs121434373 GRCh38 Chromosome 19, 12896249: 12896249
18 GCDH NM_000159.3(GCDH): c.1173G> T (p.Gly391=) single nucleotide variant Benign rs1060218 GRCh37 Chromosome 19, 13008607: 13008607
19 GCDH NM_000159.3(GCDH): c.1173G> T (p.Gly391=) single nucleotide variant Benign rs1060218 GRCh38 Chromosome 19, 12897793: 12897793
20 GCDH NM_000159.3(GCDH): c.428T> C (p.Val143Ala) single nucleotide variant Uncertain significance rs141456457 GRCh37 Chromosome 19, 13004390: 13004390
21 GCDH NM_000159.3(GCDH): c.428T> C (p.Val143Ala) single nucleotide variant Uncertain significance rs141456457 GRCh38 Chromosome 19, 12893576: 12893576
22 GCDH NM_000159.3(GCDH): c.542A> G (p.Glu181Gly) single nucleotide variant Pathogenic rs398123194 GRCh37 Chromosome 19, 13006842: 13006842
23 GCDH NM_000159.3(GCDH): c.542A> G (p.Glu181Gly) single nucleotide variant Pathogenic rs398123194 GRCh38 Chromosome 19, 12896028: 12896028
24 GCDH NM_000159.3(GCDH): c.636-1G> A single nucleotide variant Pathogenic/Likely pathogenic rs398123195 GRCh37 Chromosome 19, 13007018: 13007018
25 GCDH NM_000159.3(GCDH): c.636-1G> A single nucleotide variant Pathogenic/Likely pathogenic rs398123195 GRCh38 Chromosome 19, 12896204: 12896204
26 GCDH NM_000159.3(GCDH): c.1240G> A (p.Glu414Lys) single nucleotide variant Pathogenic rs147611168 GRCh37 Chromosome 19, 13008674: 13008674
27 GCDH NM_000159.3(GCDH): c.1240G> A (p.Glu414Lys) single nucleotide variant Pathogenic rs147611168 GRCh38 Chromosome 19, 12897860: 12897860
28 GCDH NM_000159.3(GCDH): c.262C> T (p.Arg88Cys) single nucleotide variant Pathogenic/Likely pathogenic rs142967670 GRCh38 Chromosome 19, 12891965: 12891965
29 GCDH NM_000159.3(GCDH): c.262C> T (p.Arg88Cys) single nucleotide variant Pathogenic/Likely pathogenic rs142967670 GRCh37 Chromosome 19, 13002779: 13002779
30 GCDH NM_000159.3(GCDH): c.271+1G> A single nucleotide variant Likely pathogenic rs786204639 GRCh38 Chromosome 19, 12891975: 12891975
31 GCDH NM_000159.3(GCDH): c.271+1G> A single nucleotide variant Likely pathogenic rs786204639 GRCh37 Chromosome 19, 13002789: 13002789
32 GCDH NM_000159.3(GCDH): c.383G> A (p.Arg128Gln) single nucleotide variant Likely pathogenic rs755586631 GRCh37 Chromosome 19, 13004345: 13004345
33 GCDH NM_000159.3(GCDH): c.383G> A (p.Arg128Gln) single nucleotide variant Likely pathogenic rs755586631 GRCh38 Chromosome 19, 12893531: 12893531
34 GCDH NM_000159.3(GCDH): c.416C> T (p.Ser139Leu) single nucleotide variant Pathogenic/Likely pathogenic rs139851890 GRCh37 Chromosome 19, 13004378: 13004378
35 GCDH NM_000159.3(GCDH): c.416C> T (p.Ser139Leu) single nucleotide variant Pathogenic/Likely pathogenic rs139851890 GRCh38 Chromosome 19, 12893564: 12893564
36 GCDH NM_000159.3(GCDH): c.482G> A (p.Arg161Gln) single nucleotide variant Pathogenic/Likely pathogenic rs777201305 GRCh38 Chromosome 19, 12893630: 12893630
37 GCDH NM_000159.3(GCDH): c.482G> A (p.Arg161Gln) single nucleotide variant Pathogenic/Likely pathogenic rs777201305 GRCh37 Chromosome 19, 13004444: 13004444
38 GCDH NM_000159.3(GCDH): c.533G> A (p.Gly178Glu) single nucleotide variant Likely pathogenic rs786204627 GRCh38 Chromosome 19, 12896019: 12896019
39 GCDH NM_000159.3(GCDH): c.533G> A (p.Gly178Glu) single nucleotide variant Likely pathogenic rs786204627 GRCh37 Chromosome 19, 13006833: 13006833
40 GCDH NM_000159.3(GCDH): c.769C> T (p.Arg257Trp) single nucleotide variant Pathogenic/Likely pathogenic rs766518430 GRCh38 Chromosome 19, 12896338: 12896338
41 GCDH NM_000159.3(GCDH): c.769C> T (p.Arg257Trp) single nucleotide variant Pathogenic/Likely pathogenic rs766518430 GRCh37 Chromosome 19, 13007152: 13007152
42 GCDH NM_000159.3(GCDH): c.1060G> A (p.Gly354Ser) single nucleotide variant Likely pathogenic rs768925619 GRCh38 Chromosome 19, 12897406: 12897406
43 GCDH NM_000159.3(GCDH): c.1060G> A (p.Gly354Ser) single nucleotide variant Likely pathogenic rs768925619 GRCh37 Chromosome 19, 13008220: 13008220
44 GCDH NM_000159.3(GCDH): c.1147C> T (p.Arg383Cys) single nucleotide variant Likely pathogenic rs150938052 GRCh38 Chromosome 19, 12897767: 12897767
45 GCDH NM_000159.3(GCDH): c.1147C> T (p.Arg383Cys) single nucleotide variant Likely pathogenic rs150938052 GRCh37 Chromosome 19, 13008581: 13008581
46 GCDH NM_000159.3(GCDH): c.1205G> A (p.Arg402Gln) single nucleotide variant Likely pathogenic rs786204626 GRCh38 Chromosome 19, 12897825: 12897825
47 GCDH NM_000159.3(GCDH): c.1205G> A (p.Arg402Gln) single nucleotide variant Likely pathogenic rs786204626 GRCh37 Chromosome 19, 13008639: 13008639
48 GCDH NM_000159.3(GCDH): c.1239C> A (p.Tyr413Ter) single nucleotide variant Likely pathogenic rs776082304 GRCh37 Chromosome 19, 13008673: 13008673
49 GCDH NM_000159.3(GCDH): c.1239C> A (p.Tyr413Ter) single nucleotide variant Likely pathogenic rs776082304 GRCh38 Chromosome 19, 12897859: 12897859
50 GCDH NM_000159.3(GCDH): c.675G> A (p.Trp225Ter) single nucleotide variant Likely pathogenic rs786205862 GRCh37 Chromosome 19, 13007058: 13007058

Expression for Glutaric Acidemia I

Search GEO for disease gene expression data for Glutaric Acidemia I.

Pathways for Glutaric Acidemia I

GO Terms for Glutaric Acidemia I

Sources for Glutaric Acidemia I

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....